Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C] LPM3770164 in Healthy Participants
NCT07516899Phase 1Not yet recruiting
- Sponsor
- Luye Pharma Group
- Start
- Apr 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LPM3770164 in Huntington disease (HD), sponsored by Luye Pharma Group. Primary endpoints: Recovery of total radioactivity in excreta (urine and feces) per collection period up to 40 days, Cumulative recovery of total radioactivity in excreta (urine and feces) up to 40 days and 5 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
LPM3770164
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NCT07516899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07516899.